Journal
ONCOTARGETS AND THERAPY
Volume 15, Issue -, Pages 407-410Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S315385
Keywords
adverse events; anemia; EGFR; neutropenia; non-small cell lung cancer; osimertinib; pancytopenia; thrombocytopenia
Categories
Funding
- Consorzio Interuniversitario Nazionale per la Bio Oncologia
Ask authors/readers for more resources
This case report describes a patient with EGFR-mutated NSCLC who developed pancytopenia during treatment with osimertinib, but showed excellent activity after dose reduction. This suggests that osimertinib can be safely resumed at a reduced dose even after adverse events.
Background: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib, erlotinib and standard chemotherapy. Case Presentation: Herein, we describe the case of a 69-year-old man who received first-line osimertinib for metastatic EGFRmutated NSCLC. Suspected osimertinib-induced pancytopenia together with a partial treatment response was assessed after 10 days of therapy. Osimertinib was resumed at 40 mg daily a month later while the patient exhibited durable stable disease. No other adverse events occurred. Conclusion: In the current case, first-line treatment with osimertinib at 80 mg daily in a patient with EGFR-mutated NSCLC resulted in severe pancytopenia and a rapid treatment response. Dose reduction to 40 mg daily resulted in excellent activity without any further adverse events. Osimertinib could be safely resumed at a reduced dose even after pancytopenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available